Skip to main content
Duke University Libraries
DukeSpace Scholarship by Duke Authors
  • Login
  • Ask
  • Menu
  • Login
  • Ask a Librarian
  • Search & Find
  • Using the Library
  • Research Support
  • Course Support
  • Libraries
  • About
View Item 
  •   DukeSpace
  • Duke Scholarly Works
  • Scholarly Articles
  • View Item
  •   DukeSpace
  • Duke Scholarly Works
  • Scholarly Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Survival following allogeneic transplant in patients with myelofibrosis.

Thumbnail
View / Download
854.8 Kb
Date
2020-05
Authors
Gowin, Krisstina
Ballen, Karen
Ahn, Kwang Woo
Hu, Zhen-Huan
Ali, Haris
Arcasoy, Murat O
Devlin, Rebecca
Coakley, Maria
Gerds, Aaron T
Green, Michael
Gupta, Vikas
Hobbs, Gabriela
Jain, Tania
Kandarpa, Malathi
Komrokji, Rami
Kuykendall, Andrew T
Luber, Kierstin
Masarova, Lucia
Michaelis, Laura C
Patches, Sarah
Pariser, Ashley C
Rampal, Raajit
Stein, Brady
Talpaz, Moshe
Verstovsek, Srdan
Wadleigh, Martha
Agrawal, Vaibhav
Aljurf, Mahmoud
Angel Diaz, Miguel
Avalos, Belinda R
Bacher, Ulrike
Bashey, Asad
Beitinjaneh, Amer M
Cerny, Jan
Chhabra, Saurabh
Copelan, Edward
Cutler, Corey S
DeFilipp, Zachariah
Gadalla, Shahinaz M
Ganguly, Siddhartha
Grunwald, Michael R
Hashmi, Shahrukh K
Kharfan-Dabaja, Mohamed A
Kindwall-Keller, Tamila
Kröger, Nicolaus
Lazarus, Hillard M
Liesveld, Jane L
Litzow, Mark R
Marks, David I
Nathan, Sunita
Nishihori, Taiga
Olsson, Richard F
Pawarode, Attaphol
Rowe, Jacob M
Savani, Bipin N
Savoie, Mary Lynn
Seo, Sachiko
Solh, Melhem
Tamari, Roni
Verdonck, Leo F
Yared, Jean A
Alyea, Edwin
Popat, Uday
Sobecks, Ronald
Scott, Bart L
Nakamura, Ryotaro
Mesa, Ruben
Saber, Wael
Show More
(68 total)
Repository Usage Stats
107
views
25
downloads
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF patients treated with allogeneic HCT (551 patients) and without HCT (non-HCT) (1377 patients) was analyzed with Cox proportional hazards model. Survival analysis stratified by the Dynamic International Prognostic Scoring System (DIPSS) revealed that the first year of treatment arm assignment, due to upfront risk of transplant-related mortality (TRM), HCT was associated with inferior OS compared with non-HCT (non-HCT vs HCT: DIPSS intermediate 1 [Int-1]: hazard ratio [HR] = 0.26, P < .0001; DIPSS-Int-2 and higher: HR, 0.39, P < .0001). Similarly, in the DIPSS low-risk MF group, due to upfront TRM risk, OS was superior with non-HCT therapies compared with HCT in the first-year post treatment arm assignment (HR, 0.16, P = .006). However, after 1 year, OS was not significantly different (HR, 1.38, P = .451). Beyond 1 year of treatment arm assignment, an OS advantage with HCT therapy in Int-1 and higher DIPSS score patients was observed (non-HCT vs HCT: DIPSS-Int-1: HR, 2.64, P < .0001; DIPSS-Int-2 and higher: HR, 2.55, P < .0001). In conclusion, long-term OS advantage with HCT was observed for patients with Int-1 or higher risk MF, but at the cost of early TRM. The magnitude of OS benefit with HCT increased as DIPSS risk score increased and became apparent with longer follow-up.
Type
Journal article
Subject
Science & Technology
Life Sciences & Biomedicine
Hematology
STEM-CELL TRANSPLANTATION
INTERNATIONAL WORKING GROUP
POLYCYTHEMIA-VERA
ESSENTIAL THROMBOCYTHEMIA
EUROPEAN GROUP
MYELOID METAPLASIA
SOCIETE FRANCAISE
PROGNOSTIC MODEL
PREDICT SURVIVAL
CURATIVE THERAPY
Permalink
https://hdl.handle.net/10161/20749
Published Version (Please cite this version)
10.1182/bloodadvances.2019001084
Publication Info
Gowin, Krisstina; Ballen, Karen; Ahn, Kwang Woo; Hu, Zhen-Huan; Ali, Haris; Arcasoy, Murat O; ... Saber, Wael (2020). Survival following allogeneic transplant in patients with myelofibrosis. Blood advances, 4(9). pp. 1965-1973. 10.1182/bloodadvances.2019001084. Retrieved from https://hdl.handle.net/10161/20749.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
  • Scholarly Articles
More Info
Show full item record

Scholars@Duke

Arcasoy

Murat Osman Arcasoy

Professor of Medicine
Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulat
Open Access

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy

Rights for Collection: Scholarly Articles


Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info

Make Your Work Available Here

How to Deposit

Browse

All of DukeSpaceCommunities & CollectionsAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit DateThis CollectionAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit Date

My Account

LoginRegister

Statistics

View Usage Statistics
Duke University Libraries

Contact Us

411 Chapel Drive
Durham, NC 27708
(919) 660-5870
Perkins Library Service Desk

Digital Repositories at Duke

  • Report a problem with the repositories
  • About digital repositories at Duke
  • Accessibility Policy
  • Deaccession and DMCA Takedown Policy

TwitterFacebookYouTubeFlickrInstagramBlogs

Sign Up for Our Newsletter
  • Re-use & Attribution / Privacy
  • Harmful Language Statement
  • Support the Libraries
Duke University